Search Results for

Showing 21 - 30 of 558 results
  1. Annual Meeting Program Committee

    Annual Meeting Program Committee Annual Meeting Program Committee Description The Annual Meeting Program Committee (AMPC), under the direction of the Executive Vice President, is responsible for the content of the scientific portion of the ARVO Annual Meeting. Composition The members of each Scientific Section and Cross-sectional Group elect an AMPC member from the lists of current ARVO voting members (Regular, Sustaining, or Life members) each year. The Executive Vice President serves as

  2. Annual Meeting Program Committee

    Annual Meeting Program Committee Annual Meeting Program Committee Description The Annual Meeting Program Committee (AMPC), under the direction of the Executive Vice President, is responsible for the content of the scientific portion of the ARVO Annual Meeting. Composition The members of each Scientific Section and Cross-sectional Group elect an AMPC member from the lists of current ARVO voting members (Regular, Sustaining, or Life members) each year. The Executive Vice President serves as

  3. MIN

    Members in the News Champalimaud MiN

  4. MIN

    Members in the News Champalimaud MiN

  5. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  6. ARVO Education

    ARVO Education Online Education Meet presentations Education Courses

  7. Telling the story of OCT

    Telling the story of OCT Optical coherence tomography (OCT) is a technology invented by ARVO members that helps preserve patients' sight, saves taxpayers billions of dollars and enables further discoveries in science and medicine. See how ARVO has shared the impact of OCT with vision scientists, patients, and policymakers.  OCT projects

  8. ARVO Foundation: Advancing science and careers

    ARVO Foundation Advancing science and careers Genentech AMD Research Fellowship recipients share their progress The Genentech Age-Related Macular Degeneration (AMD) Research Fellowships are awarded annually through the ARVO Foundation. The award supports two research fellowships for young investigators who are age 45 or younger, including one award for basic research in the understanding of AMD and one for translational AMD research focusing on therapeutics (not yet in clinical trials). The

  9. ARVO Foundation welcomes Chair Paul Sternberg, Jr.

    ARVO Foundation ARVO Foundation welcomes new chair Paul Sternberg, Jr. Paul Sternberg, Jr., MD, FARVO, will take the helm of the ARVO Foundation as chair of the Board of Governors in April. Sternberg has served as a Governor since 2014 and is a past ARVO Trustee representing the Retina Section. Sternberg is the G. W. Hale Professor of Ophthalmology at the Vanderbilt Eye Institute and chief medical officer and chief patient experience officer at Vanderbilt University Medical Center in Nashvil

  10. Spotlight on members: ONL Therapeutics

    Spotlight on members ONL Therapeutics: More than a one-shot wonder It’s a classic story: scientist discovers a compound with real therapeutic potential, only to have no idea how to move forward. Fortunately for David Zacks, MD, PhD, professor of ophthalmology and visual sciences at the University of Michigan Kellogg Eye Center, help was waiting on campus. Guided by the university’s technology transfer office, ONL Therapeutics was incorporated. And with Small Business Innovative Research (SBIR